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Copy number variation (CNV) is one of the major factors
contributing to genomic diversity and diseases. It has
been shown especially for neurodegenerative diseases that
CNVs can play a very important role in genetic predispo-
sition of the disease. Glaucoma is a major neurodegenera-
tive disease causing irreversible vision loss across the
globe. We wanted to analyze the impact of CNVs in a
genome-wide scale in patients of primary open angle
glaucoma (POAG) collected from the West Bengal state
of India and reproduce our results in another cohort of
Caucasian origin. Genome-wide data was generated on
347 POAG cases and 345 controls on Illumina 660W-
Quad arrays and CNVs were called using PennCNV.
The CNVs were classified as small (<100 kb) and large
(>100 kb) and analyzed seprately for their involvement in
the disease. A publicly available dataset of POAG cohort
of 624 cases and 404 controls from Caucasian origin
(GLAUGEN study) was used as a validation cohort and
genome-wide CNV data of 208 HAPMAP samples was
used as global control. We analyzed genome-wide CNV
from 1928 samples. For the large CNVs distribution was
significantly skewed toward larger size (>1 Mb) in cases
compared to controls and this was replicated in the
GLAUGEN data. We found that CNVs >1 Mb are
enriched for gene rich regions in POAG patients with
125 genes while for controls a similar percentage of large
CNVs overlapped with only 5 genes. In 208 HAPMAP
samples CNV >1 Mb overlapped with 95 genes. Interest-
ingly, genes found in the patients were unique and did
not overlap with controls or HAPMAP samples. Within
CNVs of >1 Mb gene-rich large deletions were ~2 fold
enriched in patients compared to duplications irrespective
of their ethnic background. Such a bias was not observed
in the controls. In the smaller CNV range we performed
association analysis and identifed novel regions to be
under significantly higher CNV in patients’ comapred to
controls. Particularly, a CNV encompassing the transcrip-
tion factor FOXE3 was significantly enriched in patients
of both Indian and Caucasian POAG patietns comapred
to their respective controls. A sequence analysis of the
gene revealed novel missense mutation in the patients.
We have shown that genomic CNVs >1 Mb has
significantly higher burden in POAG patient’s genome
compared to controls irrespective of the population back-
ground. We have also identified candidate genes/regions
which are uniquely present in POAG cases and absent in
controls from all over the world. Our data provide new
insights into role of CNV in pathogenesis of POAG.
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